Immatics Announces Second Quarter 2024 Financial Results and Business Update

• May 2024 clinical data on ACTengine IMA203 targeting PRAME in 30 heavily pretreated patients with metastatic melanoma in RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profile
• Registration-enabled randomized phase 2/3 trial for ACTengine IMA203 in 2L+ melanoma planned to start in 2024
• Next data update on IMA203 and IMA203CD8 (GEN2) will be presented at medical conferences in the second half of 2024
• First clinical data from dose escalation in Phase 1 of Immatics’ next generation, half-life extended TCR Bispecific, TCER IMA401 (MAGEA4/8), to be presented as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024
• First dose escalation data for next-generation TCER IMA402 (PRAME) with extended half-life to be announced later in the second half of 2024
• Appointment of Alise Reicin MD to Board of Directors
• Cash and cash equivalents, as well as other financial assets, amount to $568.5 million¹ (€531.1 million) as of June 30, 2024, financing of business activities until 2027

Houston, Texas and Tübingen, Germany, August 13, 2024 – Immatics NV (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of T-cell redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024.

“It is an exciting time for Immatics as we prepare to achieve several key clinical milestones in the second half of the year. Starting with the presentation of the first clinical data on our TCR Bispecific, TCER IMA401, at ESMO, followed by further data updates from our cell therapy pipeline and the initiation of the IMA203 registration-enabled clinical trial, we look forward to further developing our product candidates in the coming months,” said Harpreet Singh, Ph.D., CEO and co-founder of Immatics. “Patients with advanced solid tumors need transformative therapies that make a meaningful difference in their quality of life. With each clinical milestone we achieve, we move one step closer to making an impact on the lives of these patients.”